Skip to main content
main-content

11-02-2021 | ASCO GU 2021 | Conference coverage | Video

Single-agent atezolizumab supported for some cisplatin-ineligible mUC patients

Speaker: Matthew Galsky

Matthew Galsky shares exploratory data from the IMvigor130 trial suggesting the benefit of atezolizumab monotherapy in certain cisplatin-ineligible patients with advanced urothelial carcinoma (6:13).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

ESMO Congress 2021

Access our ongoing coverage including the latest news and expert video interviews.

Image Credits